^
Association details:
| Biomarker: | NPM1-ALK fusion |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
Excerpt:
A multiple relapsed NPM1-ALK+ ALCL patient treated with ceritinib achieved complete remission...
DOI:
10.1016/j.esmoop.2021.100172
